期刊
VACCINE
卷 28, 期 38, 页码 6382-6392出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.02.097
关键词
Staphylococcus aureus; IsdA; IsdB; Vaccine; Heme-iron-transport
资金
- National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Branch [AI52474]
- Novartis Vaccines and Diagnostics (Siena, Italy)
- Region V Great Lakes Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (GLRCE) [1-U54-AI-057153]
Staphylococcus aureus is the most frequent cause of bacteremia and hospital-acquired infection, however a vaccine that prevents staphylococcal disease is currently not available. Two sortase-anchored surface proteins, IsdA and IsdB, have been identified as subunit vaccines that, following active immunization, protect experimental animals against intravenous challenge with staphylococci. Here we investigate the molecular basis of this immunity and report that, when passively transferred to naive mice, purified antibodies directed against IsdA or IsdB protected against staphylococcal abscess formation and lethal intravenous challenge. When added to mouse blood, IsdA- or IsdB-specific antibodies did not promote rapid opsonophagocytic killing of wild-type staphylococci. Antibodies directed against IsdA interfered with heme-binding and IsdB antibodies perturbed the ability of this surface protein to bind hemoglobin. As the structural genes for isdA and isdB are required for heme-iron scavenging during the pathogenesis of infection, we hypothesize that IsdA and IsdB antibodies may at least in part provide protection against staphylococci by interfering with the pathogen's heme-iron scavenging mechanisms. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据